Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation

Aileen M. Gariepy, Beatrice A. Chen, Heather L. Hohmann, Sharon L. Achilles, Jennefer A. Russo, Mitchell D Creinin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Transabdominal injection of digoxin into the amniotic fluid or fetus to induce fetal demise before dilation and evacuation (D&E) abortion has become common practice since the passage of the Partial-Birth Abortion Ban Act in 2007. Study Design: We performed a prospective study to assess the feasibility of transvaginal administration of intraamniotic digoxin the day before D&E. All women between 18 0/7 and 23 5/7 weeks of gestation seeking termination from December 2009 to May 2011 were approached for study participation. Women who declined participation were asked to identify their primary rationale. For women declining study participation, transection of the umbilical cord during D&E was performed to meet the requirements of the ban. Results: Over 18 months, 134 women met study entry criteria and 108 (81%) declined to participate. Of the 26 women who enrolled, 1.0 mg undiluted digoxin was successfully administered transvaginally in 24 (92%, 95% confidence interval 75%-99%). The most common reasons for declining participation were discomfort with preoperatively inducing fetal demise (37%) and desire to avoid a medically unnecessary medication (36%). Conclusions: Transvaginal administration of digoxin is a feasible alternative to transabdominal administration to induce preoperative fetal demise. The majority of women decline digoxin administration when an alternative is available.

Original languageEnglish (US)
Pages (from-to)76-80
Number of pages5
JournalContraception
Volume87
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Digoxin
Dilatation
Fetal Death
Umbilical Cord
Amniotic Fluid
Fetus
Parturition
Prospective Studies
Confidence Intervals
Pregnancy
Injections

Keywords

  • Abortion
  • Digoxin
  • Dilation and evacuation
  • Fetal demise
  • Transvaginal

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation. / Gariepy, Aileen M.; Chen, Beatrice A.; Hohmann, Heather L.; Achilles, Sharon L.; Russo, Jennefer A.; Creinin, Mitchell D.

In: Contraception, Vol. 87, No. 1, 01.2013, p. 76-80.

Research output: Contribution to journalArticle

Gariepy, Aileen M. ; Chen, Beatrice A. ; Hohmann, Heather L. ; Achilles, Sharon L. ; Russo, Jennefer A. ; Creinin, Mitchell D. / Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation. In: Contraception. 2013 ; Vol. 87, No. 1. pp. 76-80.
@article{b410fa6a3ca647438c7a4d64c7698c07,
title = "Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation",
abstract = "Background: Transabdominal injection of digoxin into the amniotic fluid or fetus to induce fetal demise before dilation and evacuation (D&E) abortion has become common practice since the passage of the Partial-Birth Abortion Ban Act in 2007. Study Design: We performed a prospective study to assess the feasibility of transvaginal administration of intraamniotic digoxin the day before D&E. All women between 18 0/7 and 23 5/7 weeks of gestation seeking termination from December 2009 to May 2011 were approached for study participation. Women who declined participation were asked to identify their primary rationale. For women declining study participation, transection of the umbilical cord during D&E was performed to meet the requirements of the ban. Results: Over 18 months, 134 women met study entry criteria and 108 (81{\%}) declined to participate. Of the 26 women who enrolled, 1.0 mg undiluted digoxin was successfully administered transvaginally in 24 (92{\%}, 95{\%} confidence interval 75{\%}-99{\%}). The most common reasons for declining participation were discomfort with preoperatively inducing fetal demise (37{\%}) and desire to avoid a medically unnecessary medication (36{\%}). Conclusions: Transvaginal administration of digoxin is a feasible alternative to transabdominal administration to induce preoperative fetal demise. The majority of women decline digoxin administration when an alternative is available.",
keywords = "Abortion, Digoxin, Dilation and evacuation, Fetal demise, Transvaginal",
author = "Gariepy, {Aileen M.} and Chen, {Beatrice A.} and Hohmann, {Heather L.} and Achilles, {Sharon L.} and Russo, {Jennefer A.} and Creinin, {Mitchell D}",
year = "2013",
month = "1",
doi = "10.1016/j.contraception.2012.07.019",
language = "English (US)",
volume = "87",
pages = "76--80",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation

AU - Gariepy, Aileen M.

AU - Chen, Beatrice A.

AU - Hohmann, Heather L.

AU - Achilles, Sharon L.

AU - Russo, Jennefer A.

AU - Creinin, Mitchell D

PY - 2013/1

Y1 - 2013/1

N2 - Background: Transabdominal injection of digoxin into the amniotic fluid or fetus to induce fetal demise before dilation and evacuation (D&E) abortion has become common practice since the passage of the Partial-Birth Abortion Ban Act in 2007. Study Design: We performed a prospective study to assess the feasibility of transvaginal administration of intraamniotic digoxin the day before D&E. All women between 18 0/7 and 23 5/7 weeks of gestation seeking termination from December 2009 to May 2011 were approached for study participation. Women who declined participation were asked to identify their primary rationale. For women declining study participation, transection of the umbilical cord during D&E was performed to meet the requirements of the ban. Results: Over 18 months, 134 women met study entry criteria and 108 (81%) declined to participate. Of the 26 women who enrolled, 1.0 mg undiluted digoxin was successfully administered transvaginally in 24 (92%, 95% confidence interval 75%-99%). The most common reasons for declining participation were discomfort with preoperatively inducing fetal demise (37%) and desire to avoid a medically unnecessary medication (36%). Conclusions: Transvaginal administration of digoxin is a feasible alternative to transabdominal administration to induce preoperative fetal demise. The majority of women decline digoxin administration when an alternative is available.

AB - Background: Transabdominal injection of digoxin into the amniotic fluid or fetus to induce fetal demise before dilation and evacuation (D&E) abortion has become common practice since the passage of the Partial-Birth Abortion Ban Act in 2007. Study Design: We performed a prospective study to assess the feasibility of transvaginal administration of intraamniotic digoxin the day before D&E. All women between 18 0/7 and 23 5/7 weeks of gestation seeking termination from December 2009 to May 2011 were approached for study participation. Women who declined participation were asked to identify their primary rationale. For women declining study participation, transection of the umbilical cord during D&E was performed to meet the requirements of the ban. Results: Over 18 months, 134 women met study entry criteria and 108 (81%) declined to participate. Of the 26 women who enrolled, 1.0 mg undiluted digoxin was successfully administered transvaginally in 24 (92%, 95% confidence interval 75%-99%). The most common reasons for declining participation were discomfort with preoperatively inducing fetal demise (37%) and desire to avoid a medically unnecessary medication (36%). Conclusions: Transvaginal administration of digoxin is a feasible alternative to transabdominal administration to induce preoperative fetal demise. The majority of women decline digoxin administration when an alternative is available.

KW - Abortion

KW - Digoxin

KW - Dilation and evacuation

KW - Fetal demise

KW - Transvaginal

UR - http://www.scopus.com/inward/record.url?scp=84870918577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870918577&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2012.07.019

DO - 10.1016/j.contraception.2012.07.019

M3 - Article

C2 - 22959902

AN - SCOPUS:84870918577

VL - 87

SP - 76

EP - 80

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 1

ER -